Cargando…

Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.

Since the vascular endothelium is a primary site of damage after photodynamic therapy (PDT), it seemed likely that drugs which affect the vasculature may modify the outcome of PDT. Noradrenaline, propranolol, hydralazine and phenoxybenzamine inhibited photodynamic damage to tumours if these drugs we...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowled, P. A., Forbes, I. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246724/
https://www.ncbi.nlm.nih.gov/pubmed/2525402
_version_ 1782150828530860032
author Cowled, P. A.
Forbes, I. J.
author_facet Cowled, P. A.
Forbes, I. J.
author_sort Cowled, P. A.
collection PubMed
description Since the vascular endothelium is a primary site of damage after photodynamic therapy (PDT), it seemed likely that drugs which affect the vasculature may modify the outcome of PDT. Noradrenaline, propranolol, hydralazine and phenoxybenzamine inhibited photodynamic damage to tumours if these drugs were administered concurrently with HPD, 2 h before irradiation. This inhibition was associated with reduced uptake of HPD into tumours. There was no inhibition if irradiation was delayed until 24 h after administration of vasoactive drug, presumably because HPD uptake continued after the drugs had ceased to affect the vasculature. Verapamil enhanced photodynamic destruction of tumours when administered concurrently with HPD and the enhancement was associated with increased uptake of HPD into tumours. Verapamil neither increased uptake of HPD nor enhanced photodynamic destruction of cells in vitro. When verapamil was administered after irradiation, regrowth of tumours was inhibited. A similar effect was previously demonstrated with glucocorticoids. Other calcium channel blocking agents diltiazem and nifedipine had no effect on uptake of HPD or inhibition of regrowth of tumours after PDT. Inhibition of capillary or stromal ingrowth into tumours seems a plausible explanation of this effect of verapamil. This commonly used drug may be useful to enhance the efficacy of PDT.
format Text
id pubmed-2246724
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22467242009-09-10 Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative. Cowled, P. A. Forbes, I. J. Br J Cancer Research Article Since the vascular endothelium is a primary site of damage after photodynamic therapy (PDT), it seemed likely that drugs which affect the vasculature may modify the outcome of PDT. Noradrenaline, propranolol, hydralazine and phenoxybenzamine inhibited photodynamic damage to tumours if these drugs were administered concurrently with HPD, 2 h before irradiation. This inhibition was associated with reduced uptake of HPD into tumours. There was no inhibition if irradiation was delayed until 24 h after administration of vasoactive drug, presumably because HPD uptake continued after the drugs had ceased to affect the vasculature. Verapamil enhanced photodynamic destruction of tumours when administered concurrently with HPD and the enhancement was associated with increased uptake of HPD into tumours. Verapamil neither increased uptake of HPD nor enhanced photodynamic destruction of cells in vitro. When verapamil was administered after irradiation, regrowth of tumours was inhibited. A similar effect was previously demonstrated with glucocorticoids. Other calcium channel blocking agents diltiazem and nifedipine had no effect on uptake of HPD or inhibition of regrowth of tumours after PDT. Inhibition of capillary or stromal ingrowth into tumours seems a plausible explanation of this effect of verapamil. This commonly used drug may be useful to enhance the efficacy of PDT. Nature Publishing Group 1989-06 /pmc/articles/PMC2246724/ /pubmed/2525402 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Cowled, P. A.
Forbes, I. J.
Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title_full Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title_fullStr Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title_full_unstemmed Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title_short Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
title_sort modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246724/
https://www.ncbi.nlm.nih.gov/pubmed/2525402
work_keys_str_mv AT cowledpa modificationbyvasoactivedrugsoftumourdestructionbyphotodynamictherapywithhaematoporphyrinderivative
AT forbesij modificationbyvasoactivedrugsoftumourdestructionbyphotodynamictherapywithhaematoporphyrinderivative